Drug Type TIL therapy |
Synonyms |
Target- |
Action- |
Mechanism- |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
RegulationFast Track (United States) |
Start Date05 Jul 2024 |
Sponsor / Collaborator |
Start Date04 Jul 2024 |
Sponsor / Collaborator |
Start Date05 Dec 2023 |
Sponsor / Collaborator [+1] |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hepatocellular Carcinoma | Phase 1 | China | 05 Jul 2024 | |
Locally Advanced Hepatocellular Carcinoma | Phase 1 | China | 04 Jul 2024 | |
Locally Advanced Malignant Neoplasm | Phase 1 | China | 04 Jul 2024 | |
Advanced Hepatocellular Carcinoma | IND Approval | China | 24 Jan 2024 | |
Intrahepatic Cholangiocarcinoma | IND Approval | China | 24 Jan 2024 | |
Liver Cancer | IND Approval | United States | 26 Oct 2023 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
No Data |